Can chronic inflammation and organ disease contribute to sarcopenic weight loss?

Chronic inflammation and persistent organ disease can plausibly contribute to sarcopenic weight loss through converging catabolic and nutritional pathways, particularly in chronic kidney disease (CKD) and protein–energy wasting. The overall causal magnitude is variable and not well quantified across diseases.

Clinical and functional evidence

• Skeletal-muscle protein breakdown is a supported direct contributor to loss of muscle mass underlying sarcopenia. In CKD, increased proteolysis combined with impaired protein synthesis produces negative protein balance, muscle wasting, and frailty.
• In older-adult longitudinal cohorts, higher baseline IL-6 or CRP was associated with greater subsequent grip-strength decline and higher risk of substantial strength loss. Associations with muscle-mass loss, however, have been less consistent.
• Appetite loss plausibly worsens inadequate energy and protein intake and thereby negative protein balance, but it is not independently established as a cause of clinically defined sarcopenic weight loss.

Mechanistic basis

• TNF-α, IL-1β, and IL-6 can activate NF-κB/JNK signaling, impair insulin/IGF-1–Akt anabolic signaling, release FoxO-mediated catabolic programs, and induce the atrophy-related ubiquitin ligases MuRF1 and atrogin-1.
• In CKD, metabolic acidosis, insulin resistance, inflammation, and hormonal disturbance may converge on ubiquitin–proteasome proteolysis. Acidosis correction has been associated with improved muscle mass and function.
• Uremic solutes, nausea, vomiting, taste disturbance, altered satiety signaling, and cytokine signaling provide plausible, overlapping explanations for appetite suppression.

Clinical implications

• Unintentional weight loss should not be equated with sarcopenia: assessment requires low strength plus confirmation of low muscle quantity or quality. Loss of ≥5% body weight over 6–12 months warrants evaluation.

Bottom line

• Protein catabolism is a well-supported pathway to muscle loss; inflammation-, organ-disease-, and appetite-related contributions are biologically credible and clinically important, but their independent causal effects remain incompletely quantified.